Last reviewed · How we verify
NCT03629405
Assessment of the Efficacy and Barrier Protection of Two Cosmetic Products
NA trial testing C - pH 4 Cosmetic Product WO 3741 in Aged Skin in 20 participants. Completed in 9 September 2016.
9 September 2016
Quick facts
| Lead sponsor | Dr. August Wolff GmbH & Co. KG Arzneimittel |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 11 August 2016 |
| Primary completion | 9 September 2016 |
| Estimated completion | 9 September 2016 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- C - pH 4 Cosmetic Product WO 3741
- D - pH 5.8 Cosmetic Product WO 4081-1
Conditions studied
- Aged Skin — all drugs for Aged Skin →
Sponsor
Dr. August Wolff GmbH & Co. KG Arzneimittel
Who can join
Adults 50 to 75, any sex, with Aged Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study was to assess the long-term efficacy and barrier protection properties of two cosmetic products on the volar forearms of 20 elderly subjects after four weeks of treatment compared to two untreated test areas.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148
Verify or expand the search:
- PubMed search for NCT03629405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Dr. August Wolff GmbH & Co. KG Arzneimittel trials
Trials by the same sponsor.
- NCT06244615 — Clinical Trial of a Mouth and Throat Rinse for the Treatment of Acute Sore Throat · NA · completed
- NCT05863104 — Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyper · Phase 2 · completed
- NCT05211505 — Investigation of Efficacy and Tolerability of WO 2707, a MoistCream Cremolum, in Postmenopausal Women Suffering From Sym · Phase 4 · completed
- NCT04222647 — Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With · Phase 2 · completed
- NCT03658616 — Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03629405 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. August Wolff GmbH & Co. KG Arzneimittel
- Last refreshed: 14 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03629405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing